Posted on February 16th, 2026
Researchers have identified the PD-1 receptor as a target for slowing disease progression in systemic sclerosis-related interstitial lung disease (SSc-ILD), supporting the development of stem cell treatments.
Continue reading new lab findings support development of stem cell treatments for ssc-ild
Posted on February 16th, 2026
Researchers at the University of Virginia found that targeting macrophages may prevent scarring in people with scleroderma, a condition marked by excessive fibrosis.
Continue reading type of immune cell may be key driver of scleroderma scarring: study
Posted on February 2nd, 2026
Researchers identified three genes involved in fatty acid metabolism that were significantly dysregulated in systemic sclerosis (SSc) patients, suggesting abnormal fatty acid metabolism may play a role in the development of SSc.
Continue reading abnormal fatty acid metabolism may play role in scleroderma: analysis
Posted on January 29th, 2026
Researchers find CO2-Ablative Fractional Laser therapy may help reduce skin scarring in localized scleroderma patients, with promising results from a small clinical trial showing improved skin thickness and elasticity.
Continue reading cosmetic laser therapy could be repurposed for localized scleroderma
Posted on January 16th, 2026
A study published in Rheumatology International found that lower blood levels of immunoglobulin G (IgG) are linked to poorer health-related quality of life in people with systemic sclerosis, including greater pain and reduced physical function.
Continue reading antibody levels may help reflect quality of life in people with scleroderma
Posted on January 16th, 2026
The University of Queensland is seeking people with Sjögren’s syndrome to participate in clinical trials on the Sunshine Coast and Noosa, investigating an eye drop that may relieve dry eye symptoms.
Continue reading clinical trials on the sunshine coast and noosa for sjogrens syndrome
Posted on January 14th, 2026
Researchers at The University of Tokyo found that people with systemic sclerosis who have isolated anti-SSA antibodies are at higher risk of shorter survival and faster disease progression, including lung disease.
Continue reading certain antibodies tied to poorer outcomes in systemic sclerosis
Posted on December 26th, 2025
Researchers found that dexamethasone reduced inflammation and scarring in a mouse model of systemic sclerosis (SSc), also decreasing pro-inflammatory molecules produced by T-cells from SSc patients.
Continue reading dexamethasone reduces inflammation, scarring in ssc mouse model: study
Posted on December 12th, 2025
Researchers found that combination therapy improves survival in people with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH), a condition where high blood pressure affects the lungs.
Continue reading survival improves for ssc-pah patients on combination therapy
Posted on December 8th, 2025
Tomisa Starr has been taking mycophenolate for nine months to treat scleroderma, an autoimmune disease that causes organ damage if left untreated, and is experiencing difficulty sleeping as a side effect.
Continue reading on choosing medicine’s side effects over scleroderma progression